There is a high rate of kidney problems in HIV-positive patients, according to a French study reported at the fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention, in Sydney. Older age, advanced HIV disease, and being on a tenofovir-containing drug regimen for longer than a year were among the factors associated with an increased risk of renal impairment.
While renal failure—a decrease in kidney function—is believed to be common in HIV-positive patients, there have been few detailed studies looking at its prevalence and risk factors.
To explore this, Philippe Morlat, MD, and his colleagues analyzed data involving 2,588 patients enrolled in the French Aquitaine Cohort between January 2004 and August 2006.
Renal failure was defined using creatinine clearance (CRCL) rate testing. Found in the blood, creatinine is a waste product generated by the normal breakdown of muscle cells. If kidney function is impaired, creatinine removal from the blood slows down. The rate of creatinine clearance therefore helps determine how well the kidneys are functioning.
Mild renal impairment was defined as a CRCL rate between 60 and 80 mL/min. A rate of 30 to 60 mL/min defined moderate renal impairment. A rate between 10 and 30 mL/min meant severe renal impairment. End-stage impairment—complete kidney failure—was defined as a rate below 10 mL/min.
Approximately 33 percent of the study participants were male; the average age upon entering the cohort was 42 years. Approximately 92 percent were on antiretroviral (ARV) therapy—25 percent were on a tenofovir (the active ingredient in Viread and a component of Truvada and Atripla)—and the average viral load and CD4 count were 90 copies and 430 cells, respectively.
Almost 23 percent of the cohort participants had some degree of renal impairment. Approximately 18 percent of the cases were mild, 4 percent were moderate, 0.3 percent were severe, and 0.2 percent were end-stage.
Multivariate analysis of the data, a statistical technique that considers multiple variables simultaneously, indicated that being over the age of 50 was the greatest risk factor, leading to a 13.32-fold increase. A low body mass index, defined as a BMI below 22, was associated with a 3.84-fold risk increased. Being female meant a 3.22-fold increased risk. Having an AIDS diagnosis meant an increased risk of 1.32 fold.
As for ARV-treatment-related factors, only prolonged tenofovir use, defined as being on the drug for longer than a year, was associated with kidney problems—a 1.62-fold increased risk. Having an undetectable viral load translated into a 1.57-fold increased risk.
In conclusion, Dr. Morlat’s team said the prevalence of renal failure is high in HIV-positive patients. “Although advanced stages of renal impairment seem uncommon,” they write, “renal function should be carefully monitored in those HIV-positive patients with older age, low BMI, female gender, tenofovir exposure, undetectable viral load and AIDS (diagnoses).”
Source:
Morlat PJM, Deti E, Lawson-Ayayi S, et al. Prevalence and factors associated with renal failure in HIV-infected patients, ANRS Aquitaine Cohort, France [Abstract MOPEB066]. Fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, 2007.
Pipeline Preview: All The New AIDS Drugs Coming Soon Peter Staley reviews all the new experimental AIDS drugs with Dr. Joe Eron, including two non-nukes, and two new classes of drugs: CCR5 and integrase inhibitors.
Simple Test Eliminates Abacavir Risk Peter Staley asks Professor Simon Mallal from the Royal Perth Hospital about a simple new genetic test that accurately predicts if a patient is at risk for an allergic reaction to abacavir (Ziagen).
July 24, 2007
A Positive Papua New Guinean Speaks Out Against Stigma Regan Hofmann interviews Maura Elaripe Mea, the first HIV-positive woman to come forward publicly in her country. Through Igat Hope, the national network of people living with HIV/AIDS in PNG, Maura and others fight AIDS discrimination while spreading information and hope.
The Latest on Lipo: Advances & Setbacks Dr. Don Kotler discusses the latest from Sydney, both good and bad, on lipodystrophy treatments and cardiovascular risk in people with HIV.
Which HIV Meds Cause Lipoatrophy? In this videocast, Dr. Eric Daar provides an overview of which nukes, non-nukes, and protease inhibitors might cause fat loss, and which ones probably won't.
Are We Starting Treatment Early Enough? In this videocast, Dr. Fred Gordin explains why many experts think we might be waiting too long to put patients on HIV treatment.
Fauci Defends Bush's AIDS Legacy Peter Staley interviews Tony Fauci about his research on HIV "eradication," President Bush's AIDS legacy, why he likes gay men and Republicans, and that letter he wrote supporting Scooter Libby.
Regan Hofmann talks with Dr. Nancy Padian about PrEP, microbicides, and circumcision, and asks "when can my boyfriend and I stop using condoms."
Peter Staley reviews all the new experimental AIDS drugs with Dr. Joe Eron, including two non-nukes, and two new classes of drugs: CCR5 and integrase inhibitors.
Peter Staley asks Professor Simon Mallal from the Royal Perth Hospital about a simple new genetic test that accurately predicts if a patient is at risk for an allergic reaction to abacavir (Ziagen).
Regan Hofmann interviews Maura Elaripe Mea, the first HIV-positive woman to come forward publicly in her country. Through Igat Hope, the national network of people living with HIV/AIDS in PNG, Maura and others fight AIDS discrimination while spreading information and hope.
Dr. Don Kotler discusses the latest from Sydney, both good and bad, on lipodystrophy treatments and cardiovascular risk in people with HIV.
In this videocast, Dr. Eric Daar provides an overview of which nukes, non-nukes, and protease inhibitors might cause fat loss, and which ones probably won't.
In this videocast, Dr. Fred Gordin explains why many experts think we might be waiting too long to put patients on HIV treatment.
A videocast interview with Professor Brian Gazzard, an expert on HIV and aging.
Peter Staley interviews Tony Fauci about his research on HIV "eradication," President Bush's AIDS legacy, why he likes gay men and Republicans, and that letter he wrote supporting Scooter Libby.
